A research team has discovered a fundamental mechanism that helps the dreaded hospital pathogen Acinetobacter baumannii to survive. This mechanism explains why the pathogen is difficult to eradicate ...

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by ...

Credit: Getty Images. The investigational intravenous product is a combination of sulbactam, a β-lactam antibiotic, and durlobactam, a broad-spectrum β-lactamase inhibitor. The Food and Drug ...